The Q-POC machine, costing 500 pounds, can micro-analyse tumours and the genetic signatures of the disease before advising on the best type of drugs to use.
Using his garage in Uckfield, East Sussex, as a makeshift laboratory, 37-year-old Jonathan O'Halloran hit on the ground-breaking idea of releasing DNA within a barely visible sample and making multiple copies to allow an accurate diagnosis, whether cancer mutations exist and which oncology drugs will work best.
The first prototypes are in advanced trials and experts say they have the potential to prolong the lives of newly-diagnosed cancer sufferers and save the lives of millions with infectious diseases.
"We are using the device to extract, amplify and analyse DNA from tumours or other samples to make sure the patient gets a personalised service as soon as possible," said O'Halloran.
"We see this working alongside histopathologists and clinical oncologists to provide the missing link - a personalised service for cancer sufferers.
The invention is being developed by British company QuantuMDx Group in partnership with Newcastle University.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
